Analysis of prognostic factors in ewing sarcoma family of tumors

Cancer - Tập 110 Số 2 - Trang 375-384 - 2007
Carlos Rodríguez‐Galindo1, Tiebin Liu2, Matthew J. Krasin3, Jianrong Wu2, Catherine A. Billups2, Najat C. Daw1, Sheri L. Spunt1, Bhaskar N. Rao4, Victor M. Santana1, Fariba Navid1
1Department of Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee
2Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
3Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
4Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee

Tóm tắt

AbstractBACKGROUND.Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups.METHODS.The authors reviewed the records of 220 patients with ESFT who were treated on protocols at St. Jude Children's Research Hospital from 1979 to 2004. Two treatment eras were defined. Factors predictive of outcome were analyzed to identify distinct risk groups.RESULTS.The median age at diagnosis was 13.7 years (range, 1.1–25.2 years). Metastatic disease was associated with tumors measuring >8 cm (P = .002) and axial location (P = .014). The 5‐year overall survival (OS) estimate (63.5% ± 3.5%) did not appear to differ by protocol. Tumor stage and size were found to be the only independent predictors of outcome. Treatment era and type of local control therapy were found to influence the outcome of patients with localized disease. Four risk groups were defined: favorable risk (age <14 years with localized, nonpelvic tumors), intermediate risk (localized, age ≥14 years, or pelvic tumors), unfavorable‐pulmonary (isolated lung metastases), and unfavorable‐extrapulmonary (extrapulmonary metastases). The 5‐year OS estimates for these groups were 88.1% ± 4.4%, 64.9% ± 5.2%, 53.8% ± 9.4%, and 27.2% ± 7.3%, respectively (P < .001). The incidence of therapy‐related leukemia was significantly higher during the second treatment era, when more intensified regimens were used (6.1% ± 2.7% vs 0% ± 0%; P = .005).CONCLUSIONS.Risk stratification schemes such as this should be used to prospectively evaluate novel risk‐based therapies. Studies of biologic pathways may help to refine this model. Cancer 2007. © 2007 American Cancer Society.

Từ khóa


Tài liệu tham khảo

Gurney JG, 1999, Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995

10.1002/mpo.10240

10.1200/JCO.1999.17.1.180

Craft AW, 2000, EICESS 92‐Early results of an international Ewings tumour study, Med Pediatr Oncol., 35, 191

Granowetter L, 2001, Comparison of dose intensified and standard dose chemotherapy for the treatment of non‐metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group‐Children's Cancer Group phase III trial, Med Pediatr Oncol., 37, 172

10.1200/JCO.1989.7.2.208

10.1200/JCO.1992.10.11.1737

10.1002/cncr.21810

Kalbfleisch JD, 1980, The Statistical Analysis of Failure Time Data

10.1214/aos/1176350951

10.1200/JCO.1990.8.9.1514

10.1016/S0959-8049(97)00043-9

10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M

10.1002/1097-0142(19890415)63:8<1477::AID-CNCR2820630805>3.0.CO;2-8

10.1016/S0360-3016(98)00191-6

10.1054/bjoc.2001.2150

10.1200/JCO.1990.8.10.1664

10.1002/1097-0142(19800801)46:3<516::AID-CNCR2820460316>3.0.CO;2-K

10.1200/JCO.1991.9.7.1173

10.1200/JCO.1987.5.8.1191

10.1056/NEJMoa020890

10.1007/BF00570495

Sladek NE, 1984, Plasma concentration of 4‐hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation, Cancer Treat Rep., 68, 1247

10.1007/BF00686020

Boddy AV, 1993, Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children, Cancer Res., 53, 3758

10.1179/joc.1998.10.5.385

10.1200/JCO.1997.15.5.1885

Ren S, 1997, Oxidation of cyclophosphamide to 4‐hydroxycyclophosphamide and dechloroethylcyclophosphamide in human liver microsomes, Cancer Res., 57, 4229

10.1200/JCO.2000.18.17.3108

10.1200/JCO.2000.18.1.4

10.1200/JCO.2004.01.041

10.1023/A:1008208511815

10.1200/JCO.2003.10.033

10.1023/A:1013148730966

10.1200/JCO.1996.14.10.2818

10.1016/j.ejca.2003.08.022

10.1097/00043426-200007000-00008

Miser JS, 1996, Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: failure of new regimens to improve outcome, Proc Annu Meet Am Soc Clin Oncol., 15, 467

10.1200/JCO.1998.16.9.3016

10.1200/JCO.2001.19.6.1818

10.1200/JCO.2003.03.006

Thông tin
Thông tin xuất bản

Cancer

Tập 110 Số 2

375-384

Thông tin tác giả